With the SHI Financial Stabilisation Act (GKV-FinStG), the framework conditions for price negotiations for medicinal products in Germany have been made more complex and have been systematically tightened by the legislator to the disadvantage of the pharmaceutical industry. On the one hand the extend of the additional benefit and on the other hand the prices, patent protection, and previous benefit assessments of the comparative therapies have a major impact on negotiations of the reimbursement amount.
Try out our new guide, which will lead you through the various scenarios of the price negotiations following AMNOG benefit assessment. For further questions, we are happy to advise you!